THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net
S U M M A R Y
DIARY: September 4, 2008 08:30 AM Thursday;
Rod Welch
Millie 3rd treatment 7th cycle cetuximab Carboplatin 4th relapse IBC.
1...Summary/Objective
...Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
...Cetuxiab Alone Clinical Study
...Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
2...Schedule Weekly Treatments Continue on Thursdays
....Date Time Staff Sta Type Dept Loc Dur Number Cycl Trmnt
3...Labs Blood Test
4...NEUTS 1.99 Decrease 3rd Week Chemotherapy Approved
5...Chemotherapy Carboplatin Approved Blood Counts Good for Treatment
6...Blood Counts Decrease Still Good for Chemotherapy Carboplatin Approved
7...Neutropenia Case Study Missed Chemotherapy and Neupogen Treatments
8...Case Study Neutropenia 28 Treatments Neupogen Missed 4 Chemotherapy
9...Neupogen 28 Treatments Neutropenia Missed Carboplatin 4 Treatments
10...Neupogen Side Effects Case Study Indicates Good Tolerance
11...Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
12...CT Test Work Plan Arrangements to Be Prepared on 080911
..............
Click here to comment!
CONTACTS
SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment
1003 -
1003 - ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS G0 0000. ref SDS F4 0000.
100502 -
100503 -
100504 -
100505 -
100506 -
100507 -
100509 - ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS 98 TZ8I
100904 - ..
100905 - Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
100906 -
100907 - Follow up ref SDS G0 X33O, ref SDS F4 X33O.
100908 -
100909 - Millie had left mastectomy surgery on 051021. ref SDS 5 EG5L
100910 - Biopsy at that time reported no findings of cancer. Approximately 8
100911 - months later on 060707 the doctor diagnosed IBC relapse and
100912 - prescribed treatment with capecitabine and Taxotere, which had been
100913 - effective in 2005 completely eliminating signs of IBC disease.
100914 - ref SDS 6 PF3O
100915 -
100916 - 1. Cycle 09 and 01 ................... 060721, ref SDS 7 407N
100917 - 2. Cycle 10 and 02 ................... 060814, ref SDS 9 LY6O
100918 - 3. Cycle 11 and 03 ................... 060908, ref SDS 9 407N
100919 - 4. Cycle 12 and 04 ................... 060929, ref SDS 9 407N
100920 - 5. Cycle 13 and 05 ................... 061020, ref SDS 10 407N
100921 - 6. Cycle 14 and 06 ................... 061110, ref SDS 11 407N
100922 - 7. Cycle 15 and 07 ................... 061201, ref SDS 12 407N
100924 - ..
100925 - Cetuxiab Alone Clinical Study
100926 -
100927 - Follow up ref SDS G0 356I, ref SDS F4 356I.
100928 -
100929 - After 7 cycles of treatment in 2006, the doctor diagnosed IBC
100930 - disease was progressing, and so made referral to UCSF for treatment
100931 - in a clinical study of Cetuximab and Carboplatin. Millie was
100932 - randominzed for treatment with Cetuximab alone, and began weekly
100933 - treatments at UCSF on 080201.
100935 - ..
100936 - Total Cetuximab
100937 - 8. Cycle 01 and 08 and 01 01.......... 070201, ref SDS 14 SG8I
100938 - 9. Cycle 01 and 08 and 02 02.......... 070208, ref SDS 15 SG8I
100939 - 10. Cycle 01 and 08 and 03 03.......... 070215, ref SDS 16 SG8I
100940 - 11. Cycle 01 and 08 and 04 04.......... 070222, ref SDS 17 SG8I
100941 - 12. Cycle 02 and 09 and 01 05.......... 070301, ref SDS 18 SG8I
100942 - 13. Cycle 02 and 09 and 02 06.......... 070308, ref SDS 20 7T3H
100943 - 14. Cycle 02 and 09 and 03 07.......... 070315, ref SDS 21 7T3H
100944 - 15. Cycle 02 and 09 and 04 08.......... 070322, ref SDS 22 7T3H
100945 - 16. Cycle 03 and 10 and 01 09.......... 070329, ref SDS 23 7T3H
100946 - 17. Cycle 03 and 10 and 02 10.......... 070405, ref SDS 24 7T3H
100947 - 18. Cycle 03 and 10 and 03 11.......... 070412, ref SDS 25 7T3H
100948 - 19. Cycle 03 and 10 and 04 12.......... 070419, ref SDS 26 7T3H
100949 - 20. Cycle 04 and 11 and 01 13.......... 070426, ref SDS 27 7T3H
100950 - 21. Cycle 04 and 11 and 02 14.......... 070503, ref SDS 28 7T3H
100951 - 22. Cycle 04 and 11 and 03 15.......... 070510, ref SDS 29 7T3H
100952 - 23. Cycle 04 and 11 and 04 16.......... 070517, ref SDS 30 7T3H
100953 - 24. Cycle 05 and 12 and 01 17.......... 070524, ref SDS 31 7T3H
100954 - 25. Cycle 05 and 12 and 02 18.......... 070531, ref SDS 32 7T3H
100955 - 26. Cycle 05 and 12 and 03 19.......... 070607, ref SDS 33 7T3H
100956 - 27. Cycle 05 and 12 and 04 20.......... 070614, ref SDS 34 0001
100957 - 28. Cycle 06 and 13 and 01 21.......... 070621, ref SDS 35 0001
100958 - 29. Cycle 06 and 13 and 02 22.......... 070628, ref SDS 36 0001
100959 - 30. Cycle 06 and 13 and 03 23.......... 070705, ref SDS 37 0001
100960 - 31. Cycle 06 and 13 and 04 24.......... 070712, ref SDS 37 0001
100961 - 32. Cycle 07 and 14 and 01 25.......... 070719, ref SDS 38 0001
100962 - 33. Cycle 07 and 14 and 02 26.......... 070726, ref SDS 36 0001
100963 - 34. Cycle 07 and 14 and 03 27.......... 070802, ref SDS 37 0001
100964 - 35. Cycle 07 and 14 and 04 28.......... 070809, ref SDS 39 0001
100965 - 36. Cycle 08 and 15 and 01 29.......... 070816, ref SDS 40 0001
100966 - 37. Cycle 08 and 15 and 02 30.......... 070823, ref SDS 41 0001
100967 - 38. Cycle 08 and 15 and 03 31.......... 070830, ref SDS 41 0001
100968 - 39. Cycle 08 and 15 and 04 32.......... 070906, ref SDS 42 0001
100969 - 40. Cycle 09 and 16 and 01 33.......... 070920, ref SDS 43 0001
100970 - 41. Cycle 09 and 16 and 02 34.......... 070927, ref SDS 44 0001
100971 - 42. Cycle 09 and 16 and 03 35.......... 071004, ref SDS 45 0001
100972 - 43. Cycle 09 and 16 and 04 36.......... 071011, ref SDS 46 0001
100973 - 44. Cycle 10 and 17 and 01 37.......... 071018, ref SDS 47 0001
100974 - 45. Cycle 10 and 17 and 02 38.......... 071025, ref SDS 48 0001
100975 - 46. Cycle 10 and 17 and 03 39.......... 071101, ref SDS 34 0001
100976 - 47. Cycle 10 and 17 and 04 40.......... 071108, ref SDS 49 0001
100977 - 48. Cycle 11 and 18 and 01 41.......... 071115, ref SDS 50 0001
100978 - 49. Cycle 11 and 18 and 02 42.......... 071122, ref SDS 36 0001
100979 - 50. Cycle 11 and 18 and 03 43.......... 071129, ref SDS 53 0001
100980 - 51. Cycle 11 and 18 and 04 44.......... 071206, ref SDS 54 0001
100981 - 52. Cycle 12 and 19 and 01 45.......... 071213, ref SDS 57 0001
100982 - 53. Cycle 12 and 19 and 02 46.......... 071220, ref SDS 60 0001
100983 - 54. Cycle 12 and 19 and 03 47.......... 071227, ref SDS 61 0001
100984 - 55. Cycle 12 and 19 and 04 48.......... 080103, ref SDS 62 0001
100985 - 56. Cycle 13 and 20 and 01 49.......... 080110, ref SDS 65 0001
100986 - 57. Cycle 13 and 20 and 02 50.......... 080117, ref SDS 66 0001
100987 - 58. Cycle 13 and 20 and 03 51.......... 080124, ref SDS 67 0001
100988 - 59. Cycle 13 and 20 and 04 52.......... 080131, ref SDS 69 0001
100989 - 60. Cycle 14 and 21 and 01 53.......... 080207, ref SDS 73 0001
100990 - 61. Cycle 14 and 21 and 02 54.......... 080214, ref SDS 74 0001
100991 - 62. Cycle 14 and 21 and 03 55.......... 080221, ref SDS 37 0001
100992 - 63. Cycle 14 and 21 and 04 56.......... 080228, ref SDS 79 0001
100993 - 64. Cycle 15 and 22 and 01 57 01 00... 080306, ref SDS 82 TZ8I
100995 - ..
100996 - Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
100997 -
100998 - Follow up ref SDS G0 5B6J, ref SDS F4 5B6J.
100999 -
101000 - On 080207 doctor reports IBC may be spreading. ref SDS 72 GH5H
101001 - Follow up examination on 080219 Doctor Rugo diagnosed progression of
101002 - disease. ref SDS 92 3J4I Photographs show spread of IBC rash, UCSF
101003 - prescribed treatment under the 2nd Arm of the study so that Millie
101004 - now gets weekly treatment with cetuximab and with Carboplatin 3
101005 - weeks of each 4 week cycle.
101006 -
101007 - 2nd
101008 - Arm Cetuximab Carboplatin
101009 - 65. Cycle 01 15 and 22 and 02 58 02 01... 080313, ref SDS 83 TZ8I
101010 - 66. Cycle 01 15 and 22 and 03 59 03 01... 080320, ref SDS 84 TZ8I
101011 - 67. Cycle 01 15 and 22 and 04 60 04 01... 080327, ref SDS 85 TZ8I
101012 - 68. Cycle 02 16 and 23 and 01 61 05 02... 080403, ref SDS 86 TZ8I
101013 - 69. Cycle 02 16 and 23 and 02 62 06 03... 080410, ref SDS 89 TZ8I
101014 - 70. Cycle 02 16 and 23 and 03 63 07 03... 080417, ref SDS 91 TZ8I
101015 - 71. Cycle 02 16 and 23 and 04 64 08 03... 080424, ref SDS 93 TZ8I
101016 - 72. Cycle 03 17 and 24 and 01 65 09 04... 080501, ref SDS 96 5B6J
101017 - 73. Cycle 03 17 and 24 and 02 66 10 05... 080508, ref SDS 98 5B6J
101018 - 74. Cycle 03 17 and 24 and 03 67 11 05... 080515, ref SDS 99 5B6J
101019 - 75. Cycle 03 17 and 24 and 04 68 12 05... 080522, ref SDS A0 5B6J
101020 - 76. Cycle 04 18 and 25 and 01 69 13 06... 080529, ref SDS A3 5B6J
101021 - 77. Cycle 04 18 and 25 and 02 70 14 07... 080605, ref SDS A4 5B6J
101022 - 78. Cycle 04 18 and 25 and 03 71 15 08... 080612, ref SDS A7 5B6J
101023 - 79. Cycle 04 18 and 25 and 04 72 16 08... 080619, ref SDS B0 5B6J
101024 - 80. Cycle 05 19 and 26 and 01 73 17 09... 080626, ref SDS B5 5B6J
101025 - 81. Cycle 05 19 and 26 and 02 74 18 10... 080703, ref SDS C0 5B6J
101026 - 82. Cycle 05 19 and 26 and 03 75 19 11... 080710, ref SDS C3 5B6J
101027 - 83. Cycle 05 19 and 26 and 04 76 20 11... 080717, ref SDS C9 5B6J
101028 - 84. Cycle 06 20 and 27 and 01 77 21 12... 080724, ref SDS D6 5B6J
101029 - 85. Cycle 06 20 and 27 and 02 78 22 13... 080731, ref SDS E0 5B6J
101030 - 86. Cycle 06 20 and 27 and 03 79 23 14... 080807, ref SDS E6 5B6J
101031 - 87. Cycle 06 20 and 27 and 04 80 24 14... 080814, ref SDS F2 5B6J
101032 - 88. Cycle 07 21 and 28 and 01 81 25 14... 080821, ref SDS F4 5B6J
101033 - 89. Cycle 07 21 and 28 and 02 82 26 15... 080828, ref SDS G0 5B6J
101034 - 90. Cycle 07 21 and 28 and 03 83 27 16... 080904, ref SDS 0 5B6J
101036 - ..
101037 - Today is the 3rd treatment of the 7th cycle with cetuximab and
101038 - Carboplatin together. This is the 27th treatment overall with
101039 - cetuximab on the 2nd arm of the clinical study, but is only the 16th
101040 - treatment with Carboplatin due to low blood counts. Millie missed the
101041 - 1st treatment of the cycle on 080821. ref SDS F4 V94O
101042 -
101043 -
101044 -
101045 -
101046 -
1011 -
SUBJECTS
Default Null Subject Account for Blank Record
1703 -
170401 - ..
170402 - Schedule Weekly Treatments Continue on Thursdays
170403 -
170404 - Follow up ref SDS G0 1K7H, ref SDS E6 1K7H.
170405 -
170406 - The current schedule is listed on 080724. ref SDS D6 1K7H
170408 - ..
170409 - Visited with Nola about Millie's schedule for October. It needs to
170410 - skip treatment on 081030, and move treatment on Millie's return from
170411 - 081106 to 081107, per Millie's itinerary reported on 080829.
170412 - ref SDS G1 SD3J
170413 -
170414 - [...below, the schedule received from UCSF for some reason
170415 - shows treatment scheduled on 081030, ref SDS 0 YB5H, and so
170416 - appears conflicting. ref SDS 0 HH93
170418 - ..
170419 - The schedule for Neupogen is listed on 080905. ref SDS G5 WJ4O
170421 - ..
170422 - Nola submitted UCSF schedule for Millie's care over the next few
170423 - months, updating the plan received on 080724, ref SDS D6 1K7H, and
170424 - implementing the schedule Brigid submitted during the meeting with the
170425 - medical team, also, on 080724. ref SDS D5 HT6N
170427 - ..
170428 - Date Time Staff Sta Type Dept Loc Dur Number Cycl Trmnt
170429 -
170430 - 080911 0820 Catherine PEN AC1 CCINF INF 20 14821159 07 04
170431 - 080911 0900 Catherine PEN AC4 CCINF INF 60 14821156 07 04
170432 - ..
170433 - 080918 0820 Catherine PEN AC1 CCINF INF 20 14821189 08 01
170434 - * 080918 0900 Catherine PEN AC4 CCINF INF 60 14991467 08 01
170435 - * 080918 0900 Brigid RSC CHF BOG Z4F 30 14821187 08 01
170436 - * 080918 1130 Rugo PEN CHF BOG Z4F 30 14850504 08 01
170437 - Brigid
170438 - Jill
170439 - 080925 0800 Catherine PEN AC1 CCINF INF 20 14821209 08 02
170440 - 080925 0900 Catherine PEN AC4 CCINF INF 60 14821201 08 02
170441 - 081002 0820 Catherine PEN AC1 CCINF INF 20 14821224 08 03
170442 - 081002 0900 Catherine PEN AC4 CCINF INF 60 14821217 08 03
170443 - 081009 0820 Catherine PEN AC1 CCINF INF 20 14821235 08 04
170444 - 081009 0900 Catherine PEN AC4 CCINF INF 60 14821231 08 04
170445 - ..
170446 - 081016 0800 Catherine PEN AC1 CCINF INF 20 14821257 09 01
170447 - 081016 0900 Catherine PEN AC4 CCINF INF 60 14821243 09 01
170448 - * 081016 1130 Rugo PEN CHF BCC Z4F 30 14850513 09 01
170449 - Brigid
170450 - Jill
170451 - 081023 0800 Catherine PEN AC1 CCINF INF 20 14881004 09 02
170452 - 081023 0900 Catherine PEN AC4 CCINF INF 60 14881004 09 02
170453 - ..
170454 - * 081030 0800 Catherine PEN AC1 CCINF INF 20 14881017 09 03
170455 - * 081030 0900 Catherine PEN AC4 CCINF INF 60 14881533 09 03
170456 - 081107 0800 Catherine PEN AC1 CCINF INF 20 14992142 09 04
170457 - 081107 0900 Catherine PEN AC4 CCINF INF 60 14881533 09 04
170458 - 081113 0800 Catherine PEN AC1 CCINF INF 20 14992153 10 01
170459 - 081113 0830 Rugo PEN CHF BCC Z4F 30 14820731 10 01
170460 - Brigid
170461 - Jill
170462 - 081113 0900 Catherine PEN AC4 CCINF INF 60 14992147 10 01
170463 - 081120 0800 Catherine PEN AC1 CCINF INF 20 14992160 10 02
170464 - 081120 0900 Catherine PEN AC4 CCINF INF 60 14992156 10 02
170465 - ...
170466 - ...
170467 - ...
170468 - 081211 0830 Rugo PEN CHF BCC Z4F 30 14820734 11 01
170469 - Brigid
170470 - Jill
170471 - ...
170473 - ..
170474 - * Comment on schedule gaps...
170476 - ..
170477 - The schedule for 080918 shows Millie getting treatment in the Infusion
170478 - Clinic at 0900 and also seeing Brigid at 0900, and then seeing the
170479 - doctor at 1130.
170480 -
170481 - 1. Assume Mil will see Brigid at 0900, and then get treatment
170482 - after meeting with the medical team, which aligns with
170483 - prior practice.
170485 - ..
170486 - 2. Meeting with the doctor after treament on 080918 will
170487 - likely occur closer to 1200 - 1300, since treatment may not
170488 - get started until 1000, after meeting with Brigid at 0900,
170489 - and getting both cetuximab and Carboplatin will take 2+
170490 - hours.
170492 - ..
170493 - Alternatively, may be possible for the doctor to join the
170494 - meeting during the 0900 - 1000 time, which has worked well,
170495 - even if this delays starting treatment for 10 or 20
170496 - minutes.
170498 - ..
170499 - The schedule for treatment on 081030 conflicts with the vacation
170500 - schedule submitted to Nola this morning, based on review at Kaiser on
170501 - 080829, as set out in Millie's letter to UCSF later that day.
170502 - ref SDS G2 RP7Y Catherine was familiar with the schedule, however,
170503 - Nola was very busy with phone calls, and directing work of the staff,
170504 - while entering Millie's schedule. This may have caused an error.
170505 -
170506 - 1. Treatment on 081030 is for the 3rd treatment in cycle 9 for
170507 - both cetuximab and Carboplatin.
170509 - ..
170510 - Nominally, Millie will miss this treatment, and for the
170511 - following week with Carboplatin, because 081107 is the 4th
170512 - week in cycle 9.
170514 - ..
170515 - 2. Alternatively, Millie could get Carboplatin on 081107 in
170516 - order to maintain chemotherapy levels.
170518 - ..
170519 - How would this affect starting the next cycle? Would that
170520 - be pushed a week?
170521 -
170522 -
170523 -
170524 -
170525 -
170526 -
170527 -
170528 -
1706 -
SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea
2503 -
2504 - 0750
250501 - ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS G0 FW5N, ref SDS F4 FW5N.
250505 -
250506 - Adding Carboplatin to the treatment protocol now requires weekly blood
250507 - tests to determine if the immune system is strong enough for safe
250508 - chemotherapy treatment, reported on 070201, ref SDS 14 XR40, and
250509 - citing the clinical study protocol received from UCSF on 070116.
250510 - ref SDS 13 5U7Z
250512 - ..
250513 - The doctor's order for lab work was ready in the Infusion Clinic
250514 - today, implementing Millie's notice to the medical team yesterday on
250515 - 080827. ref SDS F8 P98Y
250516 -
250517 -
250518 -
250520 - ..
2506 -
2507 -
2508 - 1022
2509 -
250901 - During treatment, Catherine submitted results of the test for the 2nd
250902 - treatment of the 7th cycle. Scope is reduced from starting cycle 7 on
250903 - 080821, ref SDS F4 075H, and is the same for the 4th treatment of the
250904 - 6th cycle. ref SDS F2 075H
250905 -
250920 - ..
250921 - Log#: 080904 09:00
250922 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250923 - Type Results Units Normal ACRO Type Units Normal
250924 - ..
250925 - CBC with DIFF & PLT CT CBCD
250926 - ..
250927 - WBC COUNT 4.6 x10E9/L 3.4 - 10 WBC WBC x10-3 K/uL 3.4 - 10.0
250928 - RBC COUNT L 3.83 x10E12/L 4 - 5.2 RBC RBC x10-6 M/uL 3.60 - 5.70
250929 - HEMOGLOBIN 13.3 g/dL 12 - 15.5 HGB Hemoglobin g/dL 11.5 - 15.0
250930 - HEMATOCRIT 37.4 PERCENT 36 - 46 HCT Hematocrit % 34.0 - 46.0
250931 - MCV 98 fL 80 - 100 MCV MCV fL 80.0 - 100.0
250932 - MCH H 34.7 pg 26 - 34 MCH
250933 - MCHC 35.5 g/dL 31 - 36 MCHC
250934 - PLATELETS 213 x10E9/L 140 - 450 PLT Plt x10-3 K/uL 140 - 400
250935 -
250936 - Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250937 - Francisco, CA 94115
250938 - ..
250939 - (NEUTS x 1000 = ANC for Kaiser)
250940 - NEUTS 1.99 x10E9/L 1.8 - 6.8 N-A ANC 1500
250941 - Neutrophils Not Reported Neutrophils % 50 - 70
250943 - ..
250944 - LYMPHS 1.99 x10E9/L 0.9 - 2.9 L-A Lymphocytes % 20 - 50
250945 - MONOS 0.36 x10E9/L 0.2 - 0.8 M-A Monocyte % 0 - 11
250946 - EOS 0.18 x10E9/L 0 - 0.4 E-A Esoinophils % 1 - 5
250947 - BASOS 0.07 x10E9/L 0 - 0.1 B-A Basophil % 0 - 2
250948 - LUC/ATYP LYMPHS 0.16 x10E9/L 0.0 - 0.2 LALA
250950 - ..
250951 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250952 - Type Results Units Normal ACRO Type Units Normal
250953 - ELECTROLYTE PANEL LYTE
250954 - ..
250955 - MAGNESIUM 1.8 mg/dL 1.8 - 2.3 MG Magnesium mg/dL 1.6 - 2.3
250957 - ..
250958 - CREAT with eGFR
250959 - CREATININE L 0.40 mg/dL 0.42 - 1.06 CR Creatinine mg/dL 0.6 - 1.2
250960 -
250961 - Note: Creatinine assay changed to IDMS standardization on
250962 - February 4, 2008 causing decrease in results of approximately
250963 - 0.09 mg/dL
250965 - ..
250966 - eGFR if Caucasian >60 mL/min GFRC
250967 - eGFR if African Amer >60 mL/min GFRA
250968 -
250969 - eGFR corrected for 1.73 sq meters of body surface area
250970 - Note: eGFR is only an estimation. Please see online Lab Manual
250971 - for potential limitations.
250972 - Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250973 - CA 94115
250974 -
250975 -
250976 -
250977 -
2510 -
SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5
3403 -
340401 - ..
340402 - NEUTS 1.99 Decrease 3rd Week Chemotherapy Approved
340403 - Chemotherapy Carboplatin Approved Blood Counts Good for Treatment
340404 - Blood Counts Decrease Still Good for Chemotherapy Carboplatin Approved
340405 -
340406 - Follow up ref SDS G0 PU6K, ref SDS F4 PU6K.
340407 -
340408 - Blood counts increased this week, shown by the Lab report today with
340409 - NEUTS 1.99, ref SDS 0 QY6H, compared with NEUTS 3.09 last week on
340410 - 080828, ref SDS G0 QY6H This well above UCSF standard of 1.5 for
340411 - Millie to safely get chemotherapy treatment. Millie had Neupogen
340412 - treatment at Kaiser according to the regular schedule on 080807.
340413 -
340414 -
340415 -
340416 -
3405 -
SUBJECTS
Default Null Subject Account for Blank Record
3503 -
350401 - ..
350402 - Neutropenia Case Study Missed Chemotherapy and Neupogen Treatments
350403 - Case Study Neutropenia 28 Treatments Neupogen Missed 4 Chemotherapy
350404 - Neupogen 28 Treatments Neutropenia Missed Carboplatin 4 Treatments
350405 -
350406 - Follow up ref SDS G0 8O7I, ref SDS F4 EP7N.
350407 -
350408 - Case study on 060809 shows Millie has often received chemotherapy when
350409 - blood counts are below the standard for safe treatments, and on some
350410 - occassions has received Neupogen to increase blood counts. ref SDS 8
350411 - HV45
350413 - ..
350414 - Millie has received 28 Neupogen treatments, and missed 4 chemotherapy
350415 - treatments due to rising neutropenia, and so has received only 16 of
350416 - 20 total treatments prescribed with Carboplatin, since starting the
350417 - 2nd arm of the clinical study on 080306...
350419 - ..
350420 - Neupogen Carboplatin
350421 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350422 -
350423 - 080904 1.99 2 28 7 3 16.......... ref SDS 0 QY6H
350424 - 080828 3.09 2 26 7 2 15.......... ref SDS G0 QY6H
350425 - 080821 0.99 2 24 7 1 14 4... ref SDS F4 QY6H
350426 - 080814 1.37 0 22 6 4 14.......... ref SDS F2 QY6H
350427 - 080807 2.41 2 22 6 3 14.......... ref SDS E6 QY6H
350428 - 080731 1.92 2 20 6 2 13.......... ref SDS E0 QY6H
350429 - 080724 2.32 2 18 6 1 12.......... ref SDS D6 QY6H
350430 - 080717 2.47 1 16 5 4 11.......... ref SDS C9 QY6H
350432 - ..
350433 - On 080718 2 Neupogen treatments were cancelled at Kaiser,
350434 - ref SDS D0 9W9I, because the day before at UCSF on 080717
350435 - NUETS were high, and there was no Carboplatin chemotherapy
350436 - treatment given for the 4th week in the cycle on 080717.
350438 - ..
350439 - On 080719 the day after CT testing, Millie went to Kaiser
350440 - and received 1 Neupogen treatment as a precaution ordered
350441 - by Kaiser after bleeding trauma during failed CT test using
350442 - the Power Port the day before on 080718. ref SDS D1 SR37
350444 - ..
350445 - Neupogen Carboplatin
350446 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350447 -
350448 - 080710 5.12 2 15 5 3 11......... ref SDS C3 QY6H
350449 - 080703 2.90 2 13 5 2 10......... ref SDS C0 QY6H
350450 - 080626 1.80 2 11 5 1 09......... ref SDS B5 QY6H
350451 - 080619 0.74 1 9 4 4 08......... ref SDS B0 QY6H
350452 - 080612 3.77 2 8 4 3 08......... ref SDS A7 QY6H
350454 - ..
350455 - On 080609 Kaiser orders 2 Neupogen treatments per week in
350456 - Infusion Clinic, ref SDS A6 IL6I, for UCSF prescription in
350457 - Chemo Orders on 080529, ref SDS A6 L16I, which were
350458 - received on 080605. ref SDS A4 JN38
350460 - ..
350461 - Neupogen Carboplatin
350462 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350463 -
350464 - 080605 1.55 2 6 4 2 07......... ref SDS A4 QY6H
350465 - 080529 2.26 1 4 4 1 06......... ref SDS A3 QY6H
350466 - 080522 0.96 0 3 4 05......... ref SDS A0 QY6H
350467 - 080515 1.21 0 3 3 05 3.. ref SDS 99 QY6H
350468 - 080508 5.41 1 3 3 2 05......... ref SDS 98 QY6H
350469 - 080501 1.34 1 2 3 1 04......... ref SDS 96 QY6H
350470 - 080424 1.34 0 2 4 03......... ref SDS 93 QY6H
350471 - 080417 0.95 0 2 3 03 2.. ref SDS 91 QY6H
350472 - 080410 6.85 0 2 2 03......... ref SDS 89 QY6H
350473 - 080403 1.34 1 1 2 1 02......... ref SDS 86 QY6H
350474 - 080327 2.30 0 1 4 01......... ref SDS 85 QY6H
350475 - 080320 1.28 0 1 3 01 1.. ref SDS 84 QY6H
350476 - 080313 2.05 0 1 2 01......... ref SDS 83 QY6H
350477 - 080306 1.75 0 1 1 00......... ref SDS 82 QY6H
350478 -
350479 -
350480 -
3505 -
SUBJECTS
Default Null Subject Account for Blank Record
3603 -
360401 - ..
360402 - Neupogen Side Effects Case Study Indicates Good Tolerance
360403 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
360404 -
360405 - Follow up ref SDS G0 SB8I, ref SDS F4 SB8I.
360406 -
360407 - Last weekend, Millie reported severe, momentary back pain on two
360408 - consecutive days. ref SDS G3 VP4H
360410 - ..
360411 - Side effects of Neupogen may be lessening, reported on...
360412 -
360413 - 080831................, ref SDS G3 VP4H
360414 - 080825................, ref SDS F6 9W9I
360415 - 080810................, ref SDS F0 9W9I
360416 - 080803................, ref SDS E1 9W9I
360417 - 080726................, ref SDS D8 9W9I
360418 - 080721................, ref SDS D3 9W9I
360419 - 080713................, ref SDS C6 RM94
360420 - 080629................, ref SDS B9 6Q5J
360421 - 080628................, ref SDS B7 6Q5J
360422 -
360423 - ...suggesting increased ability to tolerate 2 Neupogen treatments per
360424 - week.
360425 -
360426 -
360427 -
3605 -
SUBJECTS
Default Null Subject Account for Blank Record
3703 -
370401 - ..
370402 - CT Test Work Plan Arrangements to Be Prepared on 080911
370403 -
370404 - Visited with Catherine.
370406 - ..
370407 - Catherine received Millie's letter to the medical team yesterday on
370408 - 080903. She was aware from the letter that Kaiser has approved using
370409 - the Huber needle to access the port at UCSF for Millie's treatment
370410 - next week. ref SDS G4 IO5Y
370412 - ..
370413 - Catherine said she will use the Huber needle that supports high
370414 - pressure injections required for CT tests.
370416 - ..
370417 - Discussed briefly understanding from Diane on 080821 that the UCSF
370418 - Infusion Clinic has standardized on using only high pressure Huber
370419 - needles, ref SDS F4 N96I, as shown in the specification received from
370420 - Catherine on 080724. ref SDS D6 MV7Y The product specification says
370421 -
370422 - Lifeguard
370423 - Safety Needle
370425 - ..
370426 - The following Lifeguard Safety Infusion Set models may be
370427 - used for Power Injection of Contrast Media with the Smart
370428 - Port CT Power Injectable Ports:, ref SDS D6 N79U
370429 -
370430 -
370431 -
370432 -
370433 -
370434 -
370435 -
370436 -
370438 - ..
3705 -
3706 -
3707 - 1230
3708 -
370801 - After Millie's treatment today, we stopped at Kaiser in Oakland to
370802 - test driving instructions for getting to Millie's CT test next week,
370803 - per above. ref SDS 0 5G4J
370805 - ..
370806 - We had problems from turning "South" rather than "North" to get to
370807 - Kaiser. We wound up on Telegraph street.
370809 - ..
370810 - Stopped and got directions.
370812 - ..
370813 - Telegraph goes to West MacArther, turn South (right), and go about 4
370814 - blocks past Kaiser on the left to Piedmont. There is a Shell station
370815 - at Piedmont and West MacArther.
370817 - ..
370818 - We turned left, which is the wrong way, and so went around the block
370819 - on Webster.
370821 - ..
370822 - Turning onto Piedmont about 50 yards there is an entrance to the
370823 - parking garage. The CT Department trailer is visible in the parking
370824 - garage.
370826 - ..
370827 - We went into the building and found the Infusion Clinic on the left,
370828 - immediately after entering the building from the parking garate and
370829 - across from the CT Department trailer.
370831 - ..
370832 - The clerk has Millie scheduled to get the CT test next Thursday at
370833 - 1330.
370835 - ..
370836 - We left the Infusion Clinic and walked over to the CT Department
370837 - trailer. The attendant also shows Millie scheduled to get a test
370838 - next Thursday.
370839 -
370840 -
370841 -
370842 -
370843 -
370844 -
370845 -
370846 -
3709 -